Promega v. Roche
This article was originally published in The Gray Sheet
European Patent Office (EPO) in Munich revokes Roche's biotechnology patent '017, which covers components critical to DNA analysis used in polymerase chain reaction (PCR) and gene sequencing, Promega announces May 31. Madison, Wisconsin-based firm, along with BD Corp., New England BioLabs and Bioline, presented data to EPO showing that others had purified the Taq DNA polymerase first and that the recombinant Taq gene was obviously based on prior art. EPO's decision to revoke the patent is consistent with 1999 San Francisco federal court ruling that Roche committed eight separate acts of fraud in obtaining its '818 patent (1"The Gray Sheet" Dec. 13, 1999, p. 16)
You may also be interested in...
Roche Molecular Systems and parent company Hoffman-La Roche intend to appeal a Dec. 7 San Francisco federal district court ruling that the firm's native Taq polymerase patent is "unenforceable" because of inequitable conduct during Cetus Corp.' s patent application process in 1986, Roche said Dec. 8.
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.